Evaluation of UML-491 in the Treatment of Vascular Headaches

Publisher Website
Google Scholar
Abstract
Introduction The chemotherapeutic prevention and treatment of vascular headache of the migraine type has been a troublesome problem. Indicative of the lack of really successful treatment is the fact that approximately 400 ways of "curing" vascular headaches have been reported in the literature. A previous pilot study of a serotonin antagonist, 1-methyl-D-lysergic acid (+) butanolamide bimaleate, was made by one of the authors, and it suggested that in many instances this compound was an effective agent in the management of migraine headache.1Similar conclusions were drawn by Sicuteri and published previously.2Further appraisal of this drug was indicated. The following is a report of a continuing study of this compound conducted at the Montefiore Hospital Headache Unit over the past 12 months. In discussing any new drug, it is well to point out pertinent points in its chemistry and pharmacology. One-Methyl-D-lysergic acid (+ ) butanolamide bimaleate (methysergide) (UML-491) is related to